| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Cheryl A London | |
| P433 | issue | 3 | |
| P304 | page(s) | 106-112 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Topics in Companion Animal Medicine | Q15759986 |
| P1476 | title | Tyrosine kinase inhibitors in veterinary medicine | |
| P478 | volume | 24 |
| Q36985519 | A multi-site feasibility study for personalized medicine in canines with osteosarcoma |
| Q51252831 | A novel approach to treatment of lymphangiosarcoma in a boxer dog. |
| Q39686603 | Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines |
| Q41934588 | Analysis of activated platelet-derived growth factor β receptor and Ras-MAP kinase pathway in equine sarcoid fibroblasts. |
| Q92541881 | Array Comparative Genomic Hybridization Analysis Reveals Significantly Enriched Pathways in Canine Oral Melanoma |
| Q39560865 | Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses |
| Q90211834 | Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning |
| Q33719838 | Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11 |
| Q40034698 | Canine mammary carcinomas: influence of histological grade, vascular invasion, proliferation, microvessel density and VEGFR2 expression on lymph node status and survival time |
| Q86517653 | Canine osteosarcoma: understanding its variability to improve treatment |
| Q38100558 | Cats and chemotherapy: treat as 'small dogs' at your peril |
| Q45875048 | Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer |
| Q55067903 | Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study. |
| Q49310990 | Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. |
| Q36873386 | Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline |
| Q26782090 | Cross-species models of human melanoma |
| Q54208733 | Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma. |
| Q45887469 | Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro |
| Q91732120 | Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells |
| Q39398666 | Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: might c-kit represent a therapeutic target? |
| Q38405932 | Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. |
| Q39698999 | Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas |
| Q48104915 | Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma. |
| Q48120081 | IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. |
| Q34570140 | Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells |
| Q34461732 | Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs |
| Q39381922 | Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth |
| Q34749804 | Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog. |
| Q99409940 | In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells |
| Q39346782 | In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines |
| Q38953223 | Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. |
| Q39575368 | Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers? |
| Q38100555 | Mammary tumours in the cat: size matters, so early intervention saves lives |
| Q48025789 | Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours |
| Q46067185 | Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog. |
| Q37333673 | Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. |
| Q39348704 | NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. |
| Q38155042 | Opportunities for bead-based multiplex assays in veterinary diagnostic laboratories |
| Q54217776 | PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis. |
| Q39330425 | PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology |
| Q42682714 | Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours. |
| Q37850467 | Portal hypertension: pathophysiology, diagnosis, and treatment |
| Q54527635 | Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. |
| Q36997336 | Presumed masitinib-induced nephrotic syndrome and azotemia in a dog. |
| Q93021928 | Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas |
| Q53313967 | Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. |
| Q38033672 | Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy |
| Q57652261 | Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017) |
| Q54613659 | Safety of masitinib mesylate in healthy cats. |
| Q54296742 | Sensitive detection of the c-KIT c.1430G>T mutation by mutant-specific polymerase chain reaction in feline mast cell tumours. |
| Q55032145 | The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. |
| Q36613243 | Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs |
| Q54322229 | c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. |
Search more.